Relatório de Análise do Tamanho, Participação e Tendências do Mercado Global de Osteoartrite do Joelho – Visão Geral do Setor e Previsão até 2033

Tamanho do mercado de osteoartrite do joelho

• O mercado global de osteoartrite do joelho foi avaliado em US$ 8,41 bilhões em 2025  e deverá atingir  US$ 17,12 bilhões em 2033 , com uma taxa de crescimento anual composta (CAGR) de 9,30% durante o período de previsão.
• O crescimento do mercado é impulsionado principalmente pela crescente prevalência da osteoartrite, especialmente entre a população idosa, juntamente com o aumento das taxas de obesidade e estilos de vida sedentários que contribuem para a degeneração articular e maior incidência da doença.
• Além disso, os avanços nas abordagens de tratamento, incluindo medicamentos modificadores da osteoartrite, terapias regenerativas , injeções de ácido hialurônico e procedimentos cirúrgicos minimamente invasivos, estão melhorando os resultados para os pacientes e ampliando a adoção terapêutica.

Análise de mercado de osteoartrite do joelho

• A osteoartrite do joelho, uma doença articular degenerativa caracterizada pela degradação da cartilagem e inflamação das articulações, está se tornando um problema crescente de saúde pública, impulsionando a demanda por abordagens eficazes de diagnóstico e tratamento em estágios iniciais e avançados da doença.
• A crescente demanda por tratamento para osteoartrite do joelho é impulsionada principalmente pelo envelhecimento da população, pelo aumento das taxas de obesidade, pela maior incidência de lesões articulares e pela maior conscientização sobre o diagnóstico precoce e as opções de tratamento a longo prazo da doença.
• A América do Norte dominou o mercado de osteoartrite do joelho com uma participação significativa de 38,6% na receita em 2025, impulsionada por uma infraestrutura de saúde avançada, altas taxas de diagnóstico, sistemas de reembolso robustos e ampla adoção de opções de tratamento avançadas. Os EUA lideram devido à pesquisa clínica sólida e à disponibilidade de cuidados ortopédicos inovadores.
• A região Ásia-Pacífico deverá ser a de crescimento mais rápido no mercado de osteoartrite do joelho durante o período de previsão, devido à rápida urbanização, ao acesso facilitado aos serviços de saúde, ao aumento dos gastos com saúde e ao envelhecimento da população, além da crescente conscientização sobre distúrbios musculoesqueléticos.
• O segmento de medicamentos dominou o mercado de osteoartrite do joelho com uma participação substancial de 46,3% em 2025, impulsionado pelo uso generalizado de analgésicos orais, anti-inflamatórios e terapias injetáveis ​​que ajudam a controlar os sintomas, reduzir a inflamação e melhorar a função articular entre os pacientes.

Escopo do relatório e segmentação do mercado de osteoartrite do joelho

Tendências do mercado de osteoartrite do joelho

“Avanços em abordagens de tratamento regenerativas e personalizadas”

• Uma tendência significativa e crescente no mercado global de osteoartrite do joelho é a adoção cada vez maior de terapias regenerativas e abordagens de tratamento personalizadas, incluindo plasma rico em plaquetas (PRP), terapia com células-tronco e planos de cuidados específicos para cada paciente, visando melhorar os resultados e retardar a progressão da doença.
• For instance, PRP injections are increasingly being used in clinical practice to reduce inflammation and promote tissue repair in early to moderate knee osteoarthritis patients, offering a minimally invasive alternative to traditional treatments. Similarly, stem cell-based therapies are being explored to regenerate cartilage and enhance joint function
• Advancements in diagnostics and imaging technologies are enabling earlier and more accurate detection of knee osteoarthritis, allowing clinicians to tailor treatment strategies based on disease severity and patient condition, thereby improving long-term management. Furthermore, the integration of digital health tools and AI-based monitoring is helping track patient progress and optimize therapy outcomes
• The shift toward non-surgical and minimally invasive interventions is transforming patient expectations, with increasing preference for therapies that reduce recovery time, hospital visits, and surgical risks while maintaining effective symptom control
• Moreover, increasing clinical research and pipeline developments focused on disease-modifying osteoarthritis drugs (DMOADs) are expected to redefine treatment paradigms by targeting the underlying disease progression rather than only symptom relief
• This trend towards innovative, patient-centric, and technology-enabled treatment solutions is reshaping clinical practices, with companies and healthcare providers focusing on expanding access to advanced therapies and improving overall quality of care in knee osteoarthritis management

Knee Osteoarthritis Market Dynamics

Driver

“Rising Prevalence of Osteoarthritis and Aging Population”

• The increasing prevalence of knee osteoarthritis due to a rapidly aging global population, combined with rising obesity rates and sedentary lifestyles, is a significant driver for the growing demand for effective treatment and diagnostic solutions
• For instance, the growing elderly population worldwide is more susceptible to joint degeneration, leading to a higher incidence of knee osteoarthritis cases requiring medical intervention and long-term disease management
• As patients experience chronic pain, stiffness, and reduced mobility, there is an increasing reliance on medications, therapies, and surgical procedures to improve quality of life and restore joint function
• Furthermore, improved awareness of early diagnosis and the availability of advanced treatment options are encouraging more individuals to seek timely medical care, contributing to higher diagnosis rates and treatment adoption
• In addition, increasing healthcare expenditure and expanding access to orthopedic care services in emerging economies are supporting wider adoption of knee osteoarthritis treatments
• Moreover, growing participation in sports and physical activities, leading to higher incidence of joint injuries, is further contributing to the rising patient pool requiring osteoarthritis management
• The growing healthcare infrastructure, coupled with increased spending on musculoskeletal disorders and advancements in orthopedic care, is further supporting market expansion across both developed and emerging economies

Restraint/Challenge

“High Treatment Costs and Limited Access to Advanced Therapies”

• Concerns surrounding the high cost of advanced treatments and limited accessibility in certain regions pose a significant challenge to broader market penetration of knee osteoarthritis therapies
• For instance, regenerative therapies such as stem cell treatments and some biologic interventions are often expensive and not widely covered by insurance, making them less accessible to a large portion of the patient population
• Addressing affordability issues through improved reimbursement policies, cost-effective treatment options, and wider availability of generic medications is crucial for increasing patient adoption and market reach. In addition, disparities in healthcare infrastructure between developed and developing regions can limit access to early diagnosis and advanced care
• While awareness of knee osteoarthritis is increasing, delays in diagnosis and treatment initiation remain common in low-resource settings, further hindering optimal disease management
• Furthermore, the need for long-term and repeated treatment cycles increases the overall financial burden on patients, limiting adherence to prescribed therapies
• In addition, variability in clinical outcomes for advanced therapies such as biologics and regenerative treatments may create hesitation among both patients and healthcare providers
• Overcoming these challenges through expanded healthcare access, policy support, and the development of affordable and scalable treatment solutions will be vital for sustained growth of the knee osteoarthritis market

Knee Osteoarthritis Market Scope

The market is segmented on the basis of treatment type, route of administration, dosage form, diagnosis, end-users, and distribution channel.

• By Treatment Type

On the basis of treatment type, the knee osteoarthritis market is segmented into medication, surgery, and therapy. The medication segment dominated the market with the largest market revenue share of 46.3% in 2025, driven by the widespread use of oral analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and injectable treatments that provide effective symptom relief and inflammation control. Patients and healthcare providers often prefer medications as the first line of treatment due to their accessibility, affordability, and non-invasive nature. The growing availability of both prescription and over-the-counter drugs further supports this segment’s dominance across all stages of the disease. In addition, increasing use of intra-articular injections such as hyaluronic acid and corticosteroids contributes to sustained demand. The segment benefits from continuous product innovations aimed at improving efficacy and reducing side effects.

The therapy segment is expected to witness the fastest growth rate of 12.8% from 2026 to 2033, fueled by increasing adoption of physical therapy, occupational therapy, and emerging regenerative approaches such as platelet-rich plasma (PRP) and stem cell therapy. These therapies are gaining traction as they focus on improving joint function, reducing pain, and delaying the need for surgical intervention. Rising patient preference for non-invasive and long-term management solutions is further accelerating adoption. Growing awareness about rehabilitation programs and lifestyle modifications is also supporting this segment. Moreover, integration of therapy with pharmacological treatments is increasingly being recognized as a comprehensive approach to disease management.

• By Route of Administration

On the basis of route of administration, the knee osteoarthritis market is segmented into oral, parenteral, and others. The oral segment dominated the market with the largest market revenue share of 52.1% in 2025, driven by the widespread use of oral medications such as NSAIDs, acetaminophen, and disease-modifying supplements that are easy to administer and widely available. Oral drugs are typically the first line of treatment due to their convenience, affordability, and patient compliance. They are extensively prescribed for managing mild to moderate symptoms and are available in both branded and generic forms. The ease of distribution through retail and hospital pharmacies further strengthens this segment’s position. In addition, continuous drug development efforts are enhancing the effectiveness and safety profiles of oral therapies.

The parenteral segment is expected to witness the fastest growth rate of 13.5% from 2026 to 2033, driven by increasing use of injectable therapies such as corticosteroids, hyaluronic acid, and biologics administered directly into the joint. These treatments provide faster and more targeted relief, making them suitable for moderate to severe cases. Growing preference for minimally invasive procedures is supporting the adoption of parenteral therapies. Furthermore, advancements in injection techniques and rising availability of outpatient procedures are contributing to segment growth. Increasing clinical acceptance of biologics and regenerative injectables is also accelerating demand in this category.

• By Dosage Form

On the basis of dosage form, the knee osteoarthritis market is segmented into tablets, injections, and others. The tablets segment dominated the market with the largest market revenue share of 48.7% in 2025, driven by the extensive use of oral solid dosage forms for pain management and inflammation control. Tablets are widely preferred due to their ease of consumption, accurate dosing, and cost-effectiveness. They are readily available through multiple distribution channels and are commonly prescribed in both acute and chronic treatment regimens. The availability of extended-release formulations and combination drugs further enhances their therapeutic value. In addition, strong patient adherence to tablet-based therapies supports sustained demand.

The injections segment is expected to witness the fastest growth rate of 14.2% from 2026 to 2033, fueled by increasing adoption of intra-articular therapies such as corticosteroid injections, hyaluronic acid, and regenerative biologics. Injections provide localized treatment with faster onset of action, making them highly effective for patients with moderate to severe symptoms. Rising preference for minimally invasive procedures and growing clinical evidence supporting injectable therapies are driving this segment. Moreover, advancements in drug delivery technologies and increasing availability of outpatient injection procedures are contributing to growth. The segment is also benefiting from increasing use of PRP and stem cell-based injectables.

• By Diagnosis

Com base no diagnóstico, o mercado de osteoartrite do joelho é segmentado em exames de imagem, análise do líquido sinovial, exames de sangue e outros. O segmento de exames de imagem dominou o mercado, com a maior participação na receita, de 57,4% em 2025, impulsionado pelo uso generalizado de raios-X, ressonância magnética e tomografia computadorizada para avaliação precisa de danos articulares, perda de cartilagem e progressão da doença. As técnicas de imagem são consideradas o padrão ouro para o diagnóstico da osteoartrite do joelho e o monitoramento de sua gravidade. Elas fornecem visualização detalhada das estruturas ósseas e de tecidos moles, permitindo uma avaliação clínica precisa. A crescente disponibilidade de tecnologias de imagem avançadas e a melhoria da infraestrutura diagnóstica reforçam ainda mais a dominância desse segmento. Além disso, a detecção precoce por meio de exames de imagem está se tornando mais comum devido à maior conscientização entre pacientes e médicos.

O segmento de exames de imagem também deverá apresentar a taxa de crescimento mais rápida, de 10,9%, entre 2026 e 2033, impulsionado pelos avanços tecnológicos em diagnóstico por imagem e pela crescente adoção de ferramentas de interpretação assistidas por inteligência artificial. A melhoria na resolução das imagens e as técnicas de escaneamento mais rápidas estão aprimorando a precisão e a eficiência diagnósticas. A crescente ênfase no diagnóstico precoce e preciso está incentivando o uso mais amplo de modalidades de imagem. Além disso, o aumento dos investimentos em saúde e a expansão de centros de diagnóstico em mercados emergentes estão impulsionando o crescimento do segmento. A integração da imagem digital com os registros eletrônicos de saúde também está otimizando os processos de diagnóstico e gerenciamento de pacientes.

• Por usuários finais

Com base nos usuários finais, o mercado de osteoartrite do joelho é segmentado em hospitais, clínicas especializadas, atendimento domiciliar e outros. O segmento de hospitais dominou o mercado com a maior participação na receita, de 49,8% em 2025, impulsionado pela disponibilidade de instalações de diagnóstico avançadas, profissionais de saúde qualificados e opções de tratamento abrangentes em um só lugar. Os hospitais servem como centros primários tanto para o diagnóstico quanto para o tratamento de casos de osteoartrite do joelho moderada a grave, incluindo intervenções cirúrgicas. A presença de equipes multidisciplinares e o acesso a equipamentos cirúrgicos e de imagem avançados fortalecem ainda mais esse segmento. Os hospitais também lidam com um grande volume de pacientes, o que contribui para sua posição dominante no mercado. Além disso, estruturas de reembolso robustas para tratamentos hospitalares sustentam o crescimento do segmento.

O segmento de cuidados domiciliares deverá apresentar a taxa de crescimento mais rápida, de 13,1%, entre 2026 e 2033, impulsionado pela crescente preferência por gerenciamento remoto de pacientes, programas de reabilitação e cuidados de longa duração em casa. A crescente adoção de plataformas de telemedicina e saúde digital permite o monitoramento e a consulta contínuos sem a necessidade de visitas ao hospital. A fisioterapia domiciliar e os planos de tratamento autogerenciados estão ganhando popularidade entre os pacientes idosos. O aumento dos custos com saúde e a conveniência de receber cuidados em casa também impulsionam esse segmento. Além disso, os avanços em dispositivos médicos portáteis e ferramentas de monitoramento remoto estão apoiando a expansão dos serviços de cuidados domiciliares.

• Por canal de distribuição

Com base no canal de distribuição, o mercado de medicamentos para osteoartrite do joelho é segmentado em farmácias hospitalares, farmácias de varejo, farmácias online e outras. O segmento de farmácias hospitalares dominou o mercado com a maior participação na receita, de 44,6% em 2025, impulsionado pelo alto volume de prescrições geradas em ambientes hospitalares e pela disponibilidade imediata de medicamentos para pacientes internados e ambulatoriais. As farmácias hospitalares desempenham um papel fundamental na dispensação de medicamentos para tratamentos pós-diagnóstico e pós-cirúrgicos. A integração das farmácias hospitalares com as unidades de tratamento garante o acesso oportuno aos medicamentos. Além disso, a presença de farmacêuticos especializados e sistemas de controle de medicamentos reforça a dominância desse segmento. A forte dependência do atendimento hospitalar para casos moderados a graves contribui ainda mais para sua posição de liderança.

O segmento de farmácias online deverá apresentar a taxa de crescimento mais rápida, de 15,3%, entre 2026 e 2033, impulsionado pela crescente digitalização, pela conveniência da entrega em domicílio e pela adoção cada vez maior de plataformas de e-commerce para produtos de saúde. Os pacientes preferem as farmácias online pela facilidade de acesso a medicamentos, preços competitivos e modelos de entrega por assinatura. A expansão dos serviços de telemedicina e das prescrições digitais está impulsionando ainda mais as vendas de medicamentos online. O aumento da penetração da internet e do uso de smartphones também está contribuindo para o crescimento do segmento, principalmente em áreas urbanas. Além disso, descontos, ampla disponibilidade de produtos e logística aprimorada estão aumentando a atratividade dos canais de farmácia online.

Análise Regional do Mercado de Osteoartrite do Joelho

• A América do Norte dominou o mercado de osteoartrite do joelho com uma participação significativa de 38,6% na receita em 2025, impulsionada por uma infraestrutura de saúde avançada, altas taxas de diagnóstico, sistemas de reembolso robustos e ampla adoção de opções de tratamento avançadas.
• Pacientes e profissionais de saúde da região se beneficiam do diagnóstico precoce, da ampla disponibilidade de terapias avançadas, como medicamentos biológicos, injetáveis ​​e procedimentos cirúrgicos minimamente invasivos, além de sistemas de reembolso bem estabelecidos.
• This widespread adoption is further supported by a rapidly aging population, high obesity rates, increasing healthcare expenditure, and a strong focus on research and clinical advancements, establishing knee osteoarthritis treatments as a key component of musculoskeletal care across both residential and clinical healthcare settings

U.S. Knee Osteoarthritis Market Insight

The U.S. knee osteoarthritis market captured the largest revenue share of 81% in North America in 2025, driven by a high prevalence of osteoarthritis, advanced healthcare infrastructure, and widespread adoption of innovative treatment options. Patients and healthcare providers are increasingly prioritizing early diagnosis and effective disease management through medications, injectable therapies, and minimally invasive procedures. The growing preference for advanced biologics, regenerative therapies, and outpatient orthopedic care further propels market growth. Moreover, the integration of digital health tools, strong reimbursement frameworks, and active clinical research are significantly contributing to the expansion of knee osteoarthritis treatment adoption across the country.

Europe Knee Osteoarthritis Market Insight

The Europe knee osteoarthritis market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by an aging population, increasing prevalence of musculoskeletal disorders, and well-established healthcare systems. The rise in awareness regarding early diagnosis and the availability of advanced treatment options such as injectables, physiotherapy, and surgical interventions is fostering market adoption. European countries are also witnessing growing investments in orthopedic care and rehabilitation services. Furthermore, supportive healthcare policies, increasing healthcare expenditure, and expanding access to diagnostic imaging and specialist clinics are contributing to the steady growth of the market across residential and clinical settings.

U.K. Knee Osteoarthritis Market Insight

The U.K. knee osteoarthritis market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing cases of osteoarthritis linked to an aging population and rising obesity rates. In addition, growing awareness regarding joint health and early intervention is encouraging patients to seek timely diagnosis and treatment. The National Health Service (NHS) plays a significant role in providing access to diagnostic and treatment services, including physiotherapy and surgical procedures. The adoption of minimally invasive treatments and rehabilitation programs is also gaining traction, supported by advancements in orthopedic care and a strong network of healthcare providers across the country.

Germany Knee Osteoarthritis Market Insight

The Germany knee osteoarthritis market is expected to expand at a considerable CAGR during the forecast period, fueled by a well-developed healthcare system, high diagnostic rates, and increasing demand for advanced orthopedic treatments. Germany’s emphasis on innovation and high-quality medical care supports the adoption of therapies such as injections, physiotherapy, and surgical interventions. The country’s aging population and growing awareness of degenerative joint diseases are key factors driving demand. In addition, strong focus on rehabilitation, preventive care, and integration of advanced imaging technologies is enhancing early diagnosis and effective management of knee osteoarthritis across both hospital and specialty clinic settings.

Asia-Pacific Knee Osteoarthritis Market Insight

The Asia-Pacific knee osteoarthritis market is poised to grow at the fastest CAGR of 12.4% during the forecast period of 2026 to 2033, driven by a rapidly aging population, increasing obesity rates, and improving healthcare infrastructure in countries such as China, Japan, and India. The region’s growing awareness of musculoskeletal disorders and expanding access to diagnostic and treatment facilities are supporting market growth. In addition, rising healthcare expenditure, government initiatives to strengthen healthcare systems, and increasing availability of affordable treatment options are driving adoption. The region is also witnessing growth in outpatient care, physiotherapy services, and minimally invasive procedures, contributing to broader market expansion.

Japan Knee Osteoarthritis Market Insight

The Japan knee osteoarthritis market is gaining momentum due to the country’s rapidly aging population and high prevalence of joint-related disorders. The demand for advanced and minimally invasive treatments is increasing, supported by Japan’s technologically advanced healthcare infrastructure. Patients and providers are increasingly adopting therapies such as intra-articular injections, physiotherapy, and surgical interventions to manage symptoms and improve mobility. In addition, strong emphasis on early diagnosis through imaging techniques and continuous monitoring is supporting effective disease management. The integration of rehabilitation services and patient-centric care approaches is further fueling growth in both hospital and outpatient settings.

India Knee Osteoarthritis Market Insight

The India knee osteoarthritis market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to the country’s large population base, rising geriatric population, and increasing prevalence of lifestyle-related risk factors such as obesity and physical inactivity. India is witnessing growing awareness regarding joint health and improved access to diagnostic services, including imaging and clinical evaluations. The availability of affordable treatment options, expansion of healthcare infrastructure, and growth of specialty orthopedic clinics are key factors propelling market growth. In addition, increasing adoption of physiotherapy, injectable therapies, and surgical procedures, along with government initiatives to improve healthcare access, is driving the expansion of the knee osteoarthritis market in the country.

Knee Osteoarthritis Market Share

The Knee Osteoarthritis industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Sanofi (France)
• GSK plc (U.K.)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Anika Therapeutics Inc. (U.S.)
• Bioventus LLC (U.S.)
• Ferring Pharmaceuticals (Switzerland)
• Seikagaku Corporation (Japan)
• Zimmer Biomet (U.S.)
• Stryker (U.S.)
• Smith & Nephew (U.K.)
• DePuy Synthes (U.S.)
• Haleon plc (U.K.)
• Ono Pharmaceutical Co., Ltd. (Japan)

What are the Recent Developments in Global Knee Osteoarthritis Market?

• In January 2026, results from a Phase 3 clinical study showed that Stempeutics’ cell therapy Stempeucel-OA demonstrated sustained clinical benefits and cartilage preservation over 24 months in knee osteoarthritis patients, suggesting potential disease-modifying effects beyond symptom relief
• In December 2025, Eli Lilly announced that its next-generation weight-loss drug retatrutide delivered substantial weight loss and significant knee osteoarthritis pain reduction in a global Phase 3 TRIUMPH-4 trial, with participants losing up to an average of ~28.7% body weight and notable improvements in pain and physical function
• In December 2025, Cipla, in partnership with Stempeutics Research, launched Ciplostem, an allogeneic mesenchymal stem cell therapy for knee osteoarthritis designed to reduce inflammation, enhance joint function, and preserve cartilage in Grade II and III patients, marking a significant orthobiologic therapy introduction
• In September 2025, a large meta-analysis published in PLOS One highlighted that non-drug therapies such as knee braces, hydrotherapy, and exercise significantly outperform traditional drug treatments in relieving knee osteoarthritis pain and improving mobility, potentially influencing clinical management guidelines
• In July 2024, early clinical data from an investigational stem cell therapy (MAG200) showed that a single injection improved pain and function for up to 12 months in ~75% of knee osteoarthritis participants, indicating ongoing innovation in regenerative approaches

SKU-54000